SCM
CADL icon

Sterling Capital Management’s Candel Therapeutics CADL Stock Holding History

Sterling Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41K Sell
331
-40
-11% -$302 ﹤0.01% 2806
2026
Q1 		$1.82K Sell
371
-139
-27% -$756 ﹤0.01% 3012
2025
Q4 		$2.88K Buy
510
+156
+44% +$839 ﹤0.01% 3015
2025
Q3 		$1.8K Buy
354
+192
+119% +$1.11K ﹤0.01% 2996
2025
Q2 		$820 Buy
162
+121
+295% +$623 ﹤0.01% 3088
2025
Q1 		$232 Buy
41
+21
+105% +$172 ﹤0.01% 3068
2024
Q4 		$174 Hold
20
– – ﹤0.01% 3129
2024
Q3 		$139 Buy
+20
New +$124 ﹤0.01% 3151

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sterling Capital Management's CADL Position: Q2 2026 in Review

Sterling Capital Management reduced its Candel Therapeutics (CADL) stake by 11% in Q2 2026, selling an estimated $302 and leaving 331 shares worth $3.41K. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

Sterling Capital Management first reported a position in CADL in Q3 2024 and has held it in 8 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Sterling Capital Management held 331 shares of Candel Therapeutics worth $3.41K as of Q2 2026.
  • Sterling Capital Management sold 40 Candel Therapeutics shares in Q2 2026, an estimated $302.
  • Candel Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2806 holding.
  • Sterling Capital Management first reported a position in Candel Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.